Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 160 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypersomnolence Disorder Clear all
Completed Phase 2 Interventional

An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy

NCT05055024
View directory record Official record
Conditions
Narcolepsy With Cataplexy, Narcolepsy, Narcolepsy Without Cataplexy
Interventions
Mazindol
Drug
Lead sponsor
NLS Pharmaceutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT05113745
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 4, 2026, 5:54 AM EDT
Completed No phase listed Observational

Development and Validation of Pediatric Narcolepsy Patient Reported Outcomes Scale

NCT05373979
View directory record Official record
Conditions
Narcolepsy, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 4, 2026, 5:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

NCT07363720
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
Interventions
TAK-861, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
11
States / cities
Redwood City, California • Brandon, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

NCT02720744
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
Interventions
FT218, Placebo
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 4, 2026, 5:54 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Operational Naps on Blood Pressure and Performance Among Night Shift Workers

NCT07217769
View directory record Official record
Conditions
Shift Work
Interventions
No-nap, 15-min nap, 30-min nap, 45-min nap, 60-min nap
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Flumazenil for the Treatment of Primary Hypersomnia

NCT01183312
View directory record Official record
Conditions
Hypersomnia, Primary Hypersomnia, Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
Flumazenil
Drug
Lead sponsor
Lynn Marie Trotti
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)

NCT06619665
View directory record Official record
Conditions
Healthy, Narcolepsy
Interventions
MK-6552, MK-6552 placebo, Modafinil, Modafinil placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Atlanta, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 4, 2026, 5:54 AM EDT
Completed No phase listed Observational

Sleep Disorders of Patients With Diseases of the Nervous System

NCT00001664
View directory record Official record
Conditions
Hypersomnia, Narcolepsy, Nervous System Disease, Sleep Disorder
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
5 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

NCT03037203
View directory record Official record
Conditions
Excessive Sleepiness, Parkinson Disease
Interventions
JZP-110, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Boulder, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 4, 2026, 5:54 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

NCT07455383
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Completed No phase listed Observational

A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

NCT02769780
View directory record Official record
Conditions
Narcolepsy
Interventions
Not listed
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Interventions
Placebo, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

NCT03772314
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
Interventions
Modafinil, Amphetamine-Dextroamphetamine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 4, 2026, 5:54 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy

NCT07493265
View directory record Official record
Conditions
Narcolepsy
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
17
States / cities
Santa Ana, California • Brandon, Florida • Medley, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Recruiting Phase 2 Interventional

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis Fatigue
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

NCT03959189
View directory record Official record
Conditions
Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Interventions
ERX-963, Placebo
Drug
Lead sponsor
Expansion Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)

NCT06525077
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
FT218, Placebo
Drug · Other
Lead sponsor
Avadel
Industry
Eligibility
18 Years to 75 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Boulder, Colorado • Winter Park, Florida • Stockbridge, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

NCT04886518
View directory record Official record
Conditions
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions
Pitolisant Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Music, Sleep and Dementia Study

NCT04157244
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Circadian Rhythm Disorders, Circadian Rhythm Sleep Disorder, Insomnia, Hypersomnia, Cognitive Impairment, Cognitive Decline, Mild Cognitive Impairment, Frontotemporal Dementia, Neurocognitive Disorders, Vascular Dementia, Sleep Disorder, Memory Impairment
Interventions
Tailored music listening intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 4, 2026, 5:54 AM EDT
Terminated Phase 1 Interventional Results available

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

NCT06179407
View directory record Official record
Conditions
Narcolepsy
Interventions
MK-6552, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Colorado Springs, Colorado • Brandon, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia

NCT07646678
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Interventions
TAK-360, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 71 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
17
States / cities
Chula Vista, California • Colorado Springs, Colorado • Brandon, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 4, 2026, 5:54 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia

NCT06644573
View directory record Official record
Conditions
Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder, REM Sleep Measurement, Insomnia, Insomnia Related to Specified Disorder, Insomnia Due to Other Mental Disorder, Insomnia Comorbid to Psychiatric Disorder, Insomnia Due to Anxiety and Fear, Insomnia Related to Another Mental Condition, Insomnia Disorders, Idiopathic Hypersomnia, Sleep Disorders, Circadian Rhythm, Post Trauma Nightmares, PTSD - Post Traumatic Stress Disorder, Sleep Quality, Anesthesia, Anxiety, Depression, Mental Health, Alzheimer Disease or Associated Disorder, Parkinsons, Circadian Rhythm, Circadian Dysregulation, PTSD, Post-Traumatic, Post-Traumatic Stress Disorder Complex, Military Combat Stress Reaction, Sleep, Military Activity, Veterans, Shift Work Sleep Disorder, Menopause Related Conditions, Pain, Cancer Pain, Athletes
Interventions
PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca, Continuous EEG Monitoring
Procedure · Drug · Device
Lead sponsor
Nyree Penn
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 4, 2026, 5:54 AM EDT
Completed No phase listed Observational

A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy

NCT04803786
View directory record Official record
Conditions
Narcolepsy
Interventions
Transition from Xyrem to Xywav
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 4, 2026, 5:54 AM EDT